0001213900-26-016910.txt : 20260217 0001213900-26-016910.hdr.sgml : 20260217 20260217080029 ACCESSION NUMBER: 0001213900-26-016910 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20260217 DATE AS OF CHANGE: 20260217 EFFECTIVENESS DATE: 20260217 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CollPlant Biotechnologies Ltd CENTRAL INDEX KEY: 0001631487 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-573643 FILM NUMBER: 26636516 BUSINESS ADDRESS: STREET 1: 4 OPPENHEIMER ST., 11TH FLOOR CITY: REHOVOT STATE: L3 ZIP: 74140 BUSINESS PHONE: 972-73-232-5600 MAIL ADDRESS: STREET 1: 4 OPPENHEIMER ST., 11TH FLOOR CITY: REHOVOT STATE: L3 ZIP: 74140 FORMER COMPANY: FORMER CONFORMED NAME: CollPlant Holdings Ltd. DATE OF NAME CHANGE: 20190620 FORMER COMPANY: FORMER CONFORMED NAME: CollPlant Biotechnologies Ltd. DATE OF NAME CHANGE: 20190619 FORMER COMPANY: FORMER CONFORMED NAME: CollPlant Holdings Ltd. DATE OF NAME CHANGE: 20150122 D 1 primary_doc.xml X0708 D LIVE 0001631487 CollPlant Biotechnologies Ltd 4 OPPENHEIMER, WEIZMANN SCIENCE PARK REHOVOT L3 ISRAEL 7670104 +972 73 232 5600 ISRAEL None CollPlant Holdings Ltd. CollPlant Biotechnologies Ltd. Corporation true Yehiel Tal COLLPLANT BIOTECHNOLOGIES LTD 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Executive Officer Director Chief Executive Officer and Interim Chairman of the Board of Directors Eran Rotem COLLPLANT BIOTECHNOLOGIES LTD 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Executive Officer Deputy Chief Executive Officer and Chief Financial Officer Oren Fahimipoor COLLPLANT BIOTECHNOLOGIES LTD 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Executive Officer Vice President, Operations Philippe Bensimon COLLPLANT BIOTECHNOLOGIES LTD 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Executive Officer Vice President, Regulatory Affairs and Quality Assurance Jasmine Seror COLLPLANT BIOTECHNOLOGIES LTD 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Executive Officer Vice President, Product Development Bowman Bagley COLLPLANT BIOTECHNOLOGIES LTD 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Executive Officer Vice President, Commercial North America Bar Abelis COLLPLANT BIOTECHNOLOGIES LTD 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Executive Officer Vice President, Legal Abraham Havron COLLPLANT BIOTECHNOLOGIES LTD 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Director Elan Penn COLLPLANT BIOTECHNOLOGIES LTD 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Director Joseph Zarzewsky COLLPLANT BIOTECHNOLOGIES LTD 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Director Hugh Evans COLLPLANT BIOTECHNOLOGIES LTD 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Director Alisa Lask COLLPLANT BIOTECHNOLOGIES LTD 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Director Other Health Care Decline to Disclose 06b false 2026-02-04 false true true true true Series A warrants and series B warrants to purchase ordinary shares, including underlying ordinary shares upon exercise. false 0 H.C. Wainwright & Co. LLC 000000375 None None 430 Park Avenue 3rd Floor New York NY NEW YORK 10022 FL FLORIDA IL ILLINOIS NV NEVADA NY NEW YORK true 4000000 4000000 0 Offering of unregistered series A warrants to purchase 1,600,000 ordinary shares, and unregistered series B warrants to purchase 1,600,000 ordinary shares. The total offering amount does not reflect warrants issued to placement agent (see Item 15). false 8 210950 true 0 H.C. Wainwright is entitled to 7.0% of gross proceeds cash fee, 1.0% of gross proceeds management fee, $35,000 non-accountable expenses, $15,950 clearing fees and warrants to purchase 96,000 ordinary shares at $1.5625/share for 5 years. This is estimated. 0 true The Company intends to use the net proceeds for general corporate purposes, which may include but are not limited to, working capital and funding research and development programs. false CollPlant Biotechnologies Ltd /s/ Eran Rotem Eran Rotem Deputy Chief Executive Officer and Chief Financial Officer 2026-02-17